Merck & CompanyvsMaxCyte

MRK and MXCT stock compared: price, dividend, valuation and results, from SEC filings.

MRK

Merck & Company, Inc.

$144.46

Value $357B

-2.23%
MRK's page

MXCT

MaxCyte, Inc.

$1.18

Value $126M

-0.84%
MXCT's page

Merck & Company (MRK) has a market value of $357B and MaxCyte (MXCT) $126M. Over the last year, with dividends, MRK moved +60.0% and MXCT -25.3%. Dividend yield: MRK 2.35%, MXCT none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    MRK$357B

    MXCT$126M

    MRK is 2,832 times MXCT

  • Revenue, 12 months

    MRK$67.4B

    MXCT$34M

    MRK is 1,960 times MXCT

  • Net income, 12 months

    MRK$2.5B

    MXCT-$28M

  • Operating margin

    MRK–

    MXCT-98.0%

  • ROIC

    MRK3.9%

    MXCT-16.0%

    19.9 points apart

  • P/E

    MRK145.6

    MXCT–

  • Dividend yield

    MRK2.4%

    MXCT0.0%

    2.4 points apart

  • 5-year return

    MRK+101.1%

    MXCT-90.2%

    191.3 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

MRK+101.1%

MXCT-90.2%

010020020222023202420252026
Returns by period
PeriodMRKWith dividendsMXCTWith dividends
1 year since November 14, 2025+60.0%Price +55.5%-25.3%Price -25.3%
3 years since November 16, 2023+55.2%+15.8% a yearPrice +41.6%-69.7%-32.9% a yearPrice -69.7%
5 years since November 15, 2021+101.1%+15.0% a yearPrice +72.6%-90.2%-37.1% a yearPrice -90.2%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

MRKMerck & CompanyMXCTMaxCyte

Valuation

MRKMXCT
Valuation
Price$144.46$1.18
Market value$357B$126M
Enterprise value (EV)$401B$25M
P/E145.6–
P/E, 5-year median14.8–
P/B8.00.8
EV/EBIT84.3–
Free cash flow yield4.1%–

Results and growth

MRKMXCT
Results and growth
Revenue, 12 months$67.4B$34M
Net income, 12 months$2.5B-$28M
Free cash flow, 12 months$14.7B-$21M
Earnings per share, 12 months$0.98-$0.26
Revenue growth, year on year1.3%-14.5%
Revenue growth a year, past+9.4%over 5 years+4.8%over 5 years
EPS growth a year, past+21.2%over 5 years–

Margins and returns on capital

MRKMXCT
Margins and returns on capital
Gross margin71.8%81.0%
Operating margin–-98.0%
Net margin3.6%-81.4%
ROIC3.9%-16.0%
ROE5.2%-16.9%

Balance sheet

MRKMXCT
Balance sheet
Cash$9.7B$101M
Total debt$53.8B$17M
Net debt / EBITDA5.7–
Interest cover2.4×–

Dividends and buybacks

MRKMXCT
Dividends and buybacks
Dividend yield2.4%–
Dividend per share, 12 months$3.40–
Dividend growth a year, past+5.8%over 5 years–
Buyback yield1.4%–
Shareholder yield3.8%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: MRK or MXCT

Didn't find what you were looking for?

Ask us
Which is bigger, Merck & Company or MaxCyte?

By market value, Merck & Company ($357B) is about 2,832.4 times MaxCyte ($126M), at today's prices.

How did MRK and MXCT stock do over the last 5 years?

Since November 15, 2021, MRK's price moved +72.6% and MXCT's -90.2%. With dividends: MRK +101.1% (+15.0% a year), MXCT -90.2% (-37.1% a year). Past returns do not predict future ones.

Which pays the higher dividend, MRK or MXCT?

The dividend yield at today's price is 2.35% for Merck & Company and none for MaxCyte. Over the last twelve months they paid $3.40 and – per share.

Which has the higher profit margins, Merck & Company or MaxCyte?

Over the last twelve months, the net margin was 3.6% for Merck & Company and -81.4% for MaxCyte, and the operating margin – and -98.0%. Revenue was $67.4B and $34M.

Which is the better investment, Merck & Company or MaxCyte?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.